VEGFA and renal cell adenocarcinoma: Cabozantinib is an oral TKI of MET, VEGFRs, and AXL initially tested in a single–arm, phase I study of advanced RCC patients resistant to VEGF and mTOR inhibitors (28) that has now entered the armamentarium of agents for patients with TKI refractory disease.